Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer

被引:0
|
作者
Hiroyuki Okuyama
Yoshinori Kagawa
Toshiki Masuishi
Saori Mishima
Hiromichi Shirasu
Koji Ando
Satoshi Yuki
Kei Muro
Takayuki Yoshino
Kentaro Yamazaki
Eiji Oki
Yoshito Komatsu
Akihito Tsuji
机构
[1] Kagawa University,Department of Clinical Oncology, Faculty of Medicine
[2] Kansai Rosai Hospital,Department of Colorectal Surgery
[3] Aichi Cancer Center Hospital,Department of Clinical Oncology
[4] National Cancer Center Hospital East,Department of Gastrointestinal Oncology
[5] Shizuoka Cancer Center,Division of Gastrointestinal Oncology
[6] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[7] Hokkaido University Hospital,Department of Gastroenterology and Hepatology
[8] Hokkaido University Hospital Cancer Center,Department of Cancer Chemotherapy
关键词
Infusion reaction; Ramucirumab; Colorectal cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2025 / 2028
页数:3
相关论文
共 50 条
  • [42] A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer
    Santoro, A.
    Comandone, A.
    Rimassa, L.
    Granetti, C.
    Lorusso, V.
    Oliva, C.
    Ronzoni, M.
    Siena, S.
    Zuradelli, M.
    Mari, E.
    Pressiani, T.
    Carnaghi, C.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1888 - 1893
  • [44] Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC): Findings from the MABEL study
    Siena, S.
    Glynne-Jones, R.
    Thaler, J.
    Adenis, A.
    Preusser, P.
    Aguilar, E. Aranda
    Aapro, M.
    Loos, A.
    Esser, R.
    Wilke, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
    Joulain, F.
    Proskorovsky, I.
    Allegra, C.
    Tabernero, J.
    Hoyle, M.
    Iqbal, S. U.
    Van Cutsem, E.
    BRITISH JOURNAL OF CANCER, 2013, 109 (07) : 1735 - 1743
  • [46] Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
    F Joulain
    I Proskorovsky
    C Allegra
    J Tabernero
    M Hoyle
    S U Iqbal
    E Van Cutsem
    British Journal of Cancer, 2013, 109 : 1735 - 1743
  • [47] Biweekly Folfox4 and Folfiri in patients with advanced colorectal cancer (ACC)
    Infusino, Stefania
    Gadaleta-Caldarola, Gennaro
    Rea, Antonio
    Filice, Aldo
    Manfredi, Caterina
    Mastroianni, Candida Maria
    Sandomenico, Claudia
    Palazzo, Salvatore
    ANNALS OF ONCOLOGY, 2005, 16 : 45 - 45
  • [48] Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
    Liang, Yi-Hsin
    Liang, Jin-Tung
    Lin, Ben-Ren
    Huang, John
    Hung, Ji-Shiang
    Lai, Shuo-Lun
    Chen, Tzu-Chun
    Tsai, Jia-Huei
    Cheng, Yung-Ming
    Tsao, Ting-Han
    Hsu, Wen-Ling
    Chen, Kuo-Hsing
    Yeh, Kun-Huei
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (10) : 2057 - 2064
  • [49] Gene expression signature for the prediction of FOLFIRI response in advanced colorectal cancer patients
    Del Rio, Maguy
    Molina, Franck
    Bascoul-Mollevi, Caroline
    Copois, Virginie
    Bibeau, Frederic
    Chalbos, Patrick
    Bareil, Corinne
    Kramar, Andrew
    Salvetat, Nicolas
    Fraslon, Caroline
    Conseiller, Emmanuel
    Granci, Virginie
    Leblanc, Benjamin
    Pau, Bernard
    Martineau, Pierre
    Ychou, Marc
    CANCER RESEARCH, 2006, 66 (08)
  • [50] Phase I/II Study of FOLFIRI in Japanese Patients with Advanced Colorectal Cancer
    Yamashita, Keishi
    Nagashima, Fumio
    Fujita, Ken-ichi
    Yamamoto, Wataru
    Endo, Hisashi
    Miya, Toshimichi
    Narabayashi, Masaru
    Kawara, Kaori
    Akiyama, Yuko
    Ando, Yuichi
    Ando, Masahiko
    Sasaki, Yasutsuna
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 204 - 209